TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription

Comparatively less toxic and more tolerated, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommendable for advanced non-small-cell lung cancer (NSCLC) patients with EGFR-sensitive mutations. Some EGFR wild-type patients with specific biomarkers also show a response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Weiwei, Xu, Wei, Li, Yan, Jiang, Wei, Li, Yue, Huang, Qiqing, Chen, Bo, Wu, Shuangshuang, Wang, Yu, Song, Weiwei, Zhao, Weihong, Wu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433914/
https://www.ncbi.nlm.nih.gov/pubmed/30911072
http://dx.doi.org/10.1038/s41419-019-1519-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433914/
https://www.ncbi.nlm.nih.gov/pubmed/30911072
http://dx.doi.org/10.1038/s41419-019-1519-z

Ejemplares similares